All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy


Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

Visual abstract | Phase III randomized, open-label study of guadecitabine vs treatment choice in R/R AML: ASTRAL-2

Mar 26, 2024
Learning objective: After reading this visual abstract, learners will be able to cite a new development in the treatment of acute myeloid leukemia.

Bookmark this article

The AML is pleased to present a visual abstract summarizing results from the phase III ASTRAL-2 trial (NCT02920008) assessing guadecitabine, a next-generation hypomethylating agent vs standard-of-care treatment in patients with relapsed/refractory acute myeloid leukemia. Results from this trial were published by Roboz et al.1 in Blood Advances.

Guadecitabine was associated with a higher rate of clinical response, and while overall survival was not improved, a survival benefit was observed in several prespecified subgroups.1.

  1. Roboz GJ, Sanz GF, Griffiths EA, et al. Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: randomized phase 3 ASTRAL-2 trial. Blood Adv. 2024. Online ahead of print. DOI: 1182/bloodadvances.2023012062


Subscribe to get the best content related to AML delivered to your inbox